{"name":"Kiora Pharmaceuticals","slug":"kiora","ticker":"KPRX","exchange":"NASDAQ","domain":"kiorapharma.com","description":"Kiora Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for ophthalmic diseases. The company's pipeline includes several promising candidates, including its lead product, KPL-404, for the treatment of dry age-related macular degeneration. With a strong presence in the ophthalmology market, Kiora is well-positioned to capitalize on the growing demand for effective treatments for eye diseases. The company's commitment to research and development has led to several key milestones, including the completion of Phase 3 trials for its lead product.","hq":"Salt Lake City, UT","founded":0,"employees":"","ceo":"Brian M. Strem","sector":"Ophthalmology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":407518,"revenueGrowth":0,"grossMargin":0,"rdSpend":10780397,"netIncome":-10835154,"cash":24253300,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"KPL-404 patent cliff ($1.5B at risk)","drug":"KPL-404","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Kiora Pharmaceuticals Announces FDA Approval of KPL-404 for Dry Age-Related Macular Degeneration","summary":"Kiora Pharmaceuticals announced that the FDA has approved KPL-404 for the treatment of dry age-related macular degeneration.","drugName":"KPL-404","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Kiora Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Kiora Pharmaceuticals reported its third quarter 2023 financial results, with revenue of $10.2 million and a net loss of $23.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-22","type":"deal","headline":"Kiora Pharmaceuticals Enters into Licensing Agreement with Novartis for KPL-404","summary":"Kiora Pharmaceuticals announced that it has entered into a licensing agreement with Novartis for its lead product, KPL-404.","drugName":"KPL-404","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONVdodGVNTEVmbl80bWhWMklVU3VnQnlkX1ZmdGFvMV81RzZ5NXpnVUVWRjc1YTFpNVFlVGM4bGJpNWV3TnlOTjBpckxXUlFoT3hSSTN4SVk3M3laMU1vT1cxbVlsd3RpTE4yVkhiUVRjUXYxX3FvSjVSNWZNQ0RXX2Zobm14MnVKSmpaaG9ORklOaU9ONHdtMHBLMXdRZWxLSWxtWG1WS0w1OTE3Nmx4akRZbHc0QVVS?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Two biotech investors back Kiora with $5M now, $19M more later - Stock Titan","headline":"Two biotech investors back Kiora with $5M now, $19M more later","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOdjBMNTRHbEZpcG9CbXZHSWtWbjNfZ25tNUZ5T2lCTVI4YTgyTnZJUFdKNmkzX3d2UVFDb3ZZVVBrQUtHc3pVVkRMN0daOUI3emtMQk9tVDl4UUtJWW9iUEJvQWpNdVo1YUYxMzVRSmpQNWZ1Z1ZBRlV2dDI3Z3FGMHgtZzM?oc=5","date":"2026-04-07","type":"pipeline","source":"StocksToTrade","summary":"Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade","headline":"Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9TZ1I0aWVfV09ZdFp0bENnTFRUcXpxem94NC05aVpsMjhkTVdsWUVkYWZhUnIxMUY5Z0J0amxZS0RPcGg1Rlp1SlBHdklHSlJZX1VqbUtXbGJQS1lJUUHSAWNBVV95cUxNVjJHOWJCQVBHN0VfbExCQ1NVZV94Uk01YndlMzh5WmkwTlJiazdUVy1UQjlkbGxSRC1LeGM4clNYdjRMN3RKSXN6ZHZmd3pfUkFONk1aNlZILUkwT0h0RklsVTg?oc=5","date":"2026-04-07","type":"pipeline","source":"Bitget","summary":"Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - Bitget","headline":"Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally?","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPX0h2SU40aWs4QWtaSlkzMVJ0Vm9RSTRzMUhScWNUN3F4bXN2WFFPLWtEZEVsRm9ORHBneFFwQjRNei1RT0YweUFTUnhwNkZGMFNXdnJMRnlSMXlONjVlWTkyTW94Qi03RFIwSmp0NmRGc3hZb0VRV1ZudlRVcy1rY2JjQ1JtSUhWOS1BYnVuMVdRaHlHeGVXZXpWaF9ORS14WHQ2VldrRW01ZnlUQmhFN2VHVTk?oc=5","date":"2026-04-02","type":"trial","source":"Stock Titan","summary":"Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan","headline":"Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNd21qc25HY0NmcHZEc3ktaVlJNmZObXpDSmNiSDJQUXpSZFNYNmNQVEFfVi12djA5VnVVS0hXNDhkNmpyQ0FkZzRTWUo4SkFWU2RMTnlYZDlFODRQR3BEM21rV1VUdVpUVmJpWEgzWUlja09OWGI4a2hsdHZjb1Fpb1VfU0Y3SFVPSUNNdGNocVF5RlRvLW1DWW43bEtHLTFiV3FVOA?oc=5","date":"2026-04-02","type":"trial","source":"Stock Titan","summary":"Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan","headline":"Kiora says retinal disease trials keep enrolling after exec exit","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOeFRzb2ctNFlwaG5abm1HQktueW1wXzd4cEJTblpvd0tOMjFnSlVaNXBoNGpiZy1KbnJJcGdXQkN5SUFjanRMUUo4cHllbUhjSm93TjE2aml5VHo2SFlpT2RZMDVKTW5IcG8tNlh5a1FnXzFqZUItV0w0VVpHZTl5cXFudHdMNmNrZ1lOWEplUThmWGphSjQtUllvbGVLcWhCQUNaZWxpNXU5NC1reTZJSnVUY2swOWFycUlTY3NOZzhRbVNPR19maTZjWVY1Q1JpRWJJMDQ1WDZFMXhqcnNoQ2R1UjdORUhiYzYwN01wNkFhcFNEOXRUUk90VmtuRktuUWNhYnM2dThjTEZwQ3VGSk1vSTBybnpITkZOZjN2TnA?oc=5","date":"2026-03-25","type":"trial","source":"TMX Newsfile","summary":"Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - TMX Newsfile","headline":"Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with ","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5ITTJNaWRpekM1Sk15U3dpdTAxZWRkY0x4eXFfSUIzX0VlZDVneG9mRHd2Z1lTVkcwa20zSUVUcktib0pQZ1Q4MXlzdl9iY2l1UGZhRXBRWmYzakxFLUMtYkNlYkJGYnZQd09WRUZn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan","headline":"If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOSFJFTlNCNlozdWF4bmtOSWJZSnl6MWR5c0FUX2F3a3JxMWdxZ0hrTGNsQU8yQlRJWGszTV9oN2tNNkhHZGZTcjJkRlA4ZU5NdWtaYW1LX05UdXNwMlhSRkRFTFAyTUR1dkxCdDNLS1g5R0o1STdrc0djUEdLS0NhWngyMmNnNTFqZERKRFBSa3BtbTdGYzJPbGFGbTNBOTJnSGx2MFVjaXJydXVfVC1HMUNqTktfek9MQTRqYkdhb21KMkFSWk5DWjRBTkFWMzMxNTVKMEJ5MA?oc=5","date":"2026-02-19","type":"pipeline","source":"TMX Newsfile","summary":"Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile","headline":"Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPd0NkemtpcDlYSzhSZ0J4Y09tUjVvdHJGZE5UaXdTRy0wc1VmMnAtS2J6NXU0X2hHVUxVWnNadXNMa2ZyRzhROUIzOXVhc0NBZ1pZN0JHWnlCUEhXOHktZUFzTjdKM21uSkpWUG9Ca2cxblExVDJ1Q3VVX1dHN2I4czUzSVFqVHVRR1J2ZXdvOTZRTGJQT0pKLTdxVERCWHRzRXdUb21CS2d0cVVYVU5TS3VKdGczN1Y1ME5YVk8xN2hjNnJ5VWxIXzl1b0ZWbGtwb0ZxVjNKbEs4VHkyb09FN1BVY3NucUFsXzVJOFpaTkFjdEoxZnlCQVUzX3lrX00?oc=5","date":"2025-12-01","type":"patent","source":"TMX Newsfile","summary":"Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - TMX Newsfile","headline":"Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory C","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[{"drugName":"KPL-404","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Allergan","Bausch Health"],"therapeuticFocus":["Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":16020000,"period":"2024-12-31"},{"value":16020000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":1652520,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10780397,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-10835154,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":24253300,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}